UniSuper Management Pty Ltd Boosts Stake in Zoetis Inc. $ZTS

Key Points

• UniSuper Management Pty Ltd increased its stake in Zoetis Inc. by 6.1%, acquiring an additional 1,900 shares in the first quarter, bringing its total holdings to 33,076 shares valued at $5,446,000.
• Zoetis Inc. reported earnings of $1.76 per share for the last quarter, exceeding analysts' expectations of $1.62, with a revenue of $2.46 billion, up 4.2% year-over-year.
• Analysts have varied opinions on Zoetis, with ratings reflecting a mix of Buy and Hold, leading to an average price target of $202.43 for the stock.

UniSuper Management Pty Ltd raised its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 6.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,076 shares of the company's stock after buying an additional 1,900 shares during the quarter. UniSuper Management Pty Ltd's holdings in Zoetis were worth $5,446,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ZTS. Nuveen LLC purchased a new position in Zoetis during the first quarter valued at $616,375,000. Sarasin & Partners LLP bought a new stake in shares of Zoetis in the 1st quarter worth $339,111,000. Mackenzie Financial Corp increased its holdings in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock worth $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after purchasing an additional 1,747,423 shares in the last quarter. Finally, Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Argus reissued a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Performance

Shares of ZTS traded up $1.24 during trading hours on Thursday, hitting $150.66. The stock had a trading volume of 3,193,921 shares, compared to its average volume of 2,247,475. The stock has a fifty day moving average price of $152.70 and a 200 day moving average price of $157.56. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market capitalization of $66.77 billion, a PE ratio of 25.93, a PEG ratio of 2.40 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.